Following the same principle that other regions in self-immunogenic Ro52 variants should be targeted by autoantibodies in SLE, we looked for antibodies against the unique C-terminal sequence found in Ro52γ (hereafter Ro52γCT). This evidence concerns the gene TRIM21 and systemic lupus erythematosus.